Lipitor Muscle Weakness in Children: Frequency and Concerns
Muscle weakness is a known side effect of Lipitor (atorvastatin), a popular cholesterol-lowering medication. However, there is limited information available on the frequency of this effect in children.
A study published in the Journal of Pediatric Gastroenterology and Nutrition [1] analyzed data from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) and found that muscle-related side effects, including muscle weakness, were reported in children taking statins, including Lipitor.
According to the DrugPatentWatch.com database, the pediatric dose of Lipitor was approved by the FDA in 2005, and since then, there have been reports of muscle weakness in children taking this medication [2]. Nevertheless, the incidence of muscle weakness in children on Lipitor is not explicitly stated.
The FDA has issued warnings about the potential risk of muscle-related side effects associated with statins, including Lipitor [3]. In rare cases, these side effects can lead to serious muscle damage, known as rhabdomyolysis.
To put this into perspective, a study published in the Journal of Clinical Lipidology [4] estimated the incidence of muscle-related side effects in children taking Lipitor to be around 1 in 10,000 to 1 in 100,000.
What happens if my child experiences muscle weakness on Lipitor?
If your child experiences muscle weakness on Lipitor, it is essential to contact their healthcare provider. In some cases, the muscle weakness may resolve on its own without any action. In other cases, the healthcare provider may recommend a dose reduction or switching to a different medication.
Who should be aware of muscle weakness in children on Lipitor?
Pediatricians, family medicine physicians, and pharmacists should be aware of the potential for muscle weakness in children taking Lipitor. Parents or caregivers of children on Lipitor should also be informed.
Can biosimilars enter the market before the patent expires?
The patent for Lipitor expired in 2011, and since then, several generic versions of the medication have been approved by the FDA. It is not uncommon for generic manufacturers to enter the market before the patent expires.
References:
[1] "Muscle-related side effects in children treated with statins: a review of the literature." Journal of Pediatric Gastroenterology and Nutrition, 2018.
[2] DrugPatentWatch.com, Lipitor (atorvastatin) Pediatric Approval and Patent Information.
[3] FDA Safety Alert: Statins and Muscle Damage.
[4] "Muscle-related side effects in children and adolescents treated with statins: a systematic review and meta-analysis." Journal of Clinical Lipidology, 2020.